Introduction
Pneumocystis jirovecii (P. jirovecii) is an important opportunistic pathogen responsible for life -threatening Pneumocystis pneumonia (PCP) in immunocompromised individuals particularly in those infected with Human Immunodeficiency Virus (HIV) [1] . However, the occurrence of PCP in non-HIV immunocompromised patients is infrequent although there are a number of underlying conditions that predispose such patients to PCP, i.e., patients with malignant disorders [2] , bone marrow and solid organ transplant recipients [3] , autoimmune or infl ammatory diseases, connective tissue disorders [4, 5] and others that lead to immune system alterations [6] .
In developing countries, an increasing trend of PCP has been noted in individuals with HIV/AIDS [7] as part of the concurrent AIDS epidemic. Further, it was also observed that the incidence of PCP is not rare in immunocompromised individuals without HIV/AIDS [8] . In fact , mortality rates of 30 -50% due to PCP have been
Materials and methods
During the 3-year study period (December 2006 to December 2009), a total of 425 non-HIV immunocompromised patients attending our tertiary health care centre were screened, of which 203 patients with a high index of clinical suspicion of PCP were enrolled for further study. Demographic and necessary clinical information for each patient were collected prospectively during their visits to the hospital, as well as by reviewing their medical records. The study was approved by the institute ' s research and ethics committee.
A total of 226 clinical respiratory samples were obtained from 203 patients that included 113 bronchoalveolar lavage fl uid (BALF), 21 tracheal aspirates (TAs), 32 sputa, one gastric aspirate (GA), 58 nasopharyngeal aspirates (NPAs) and samples from only one lung biopsy. All clinical samples, except sputa, were spun at 4000 rpm at 4 ° C for 10 minutes. Each sputum sample was treated with 0.0065 M dithiothreitol (DTT), a mucolytic agent and then centrifuged. The pellets obtained was re-suspended in 1/5th of the supernatant and 200 μ l of each pellet was used for extraction of genomic DNA using commercial Qiagen tissue kit (Qiagen, USA).
Detection and identifi cation of P. jirovecii was done using commercially available direct fl uorescent antibody (DFA) staining kit (Merifl our, France) [14], Grocott ' s methenamine silver (GMS) [15] staining, as well as by amplifi cation of the major surface glycoprotein (MSG) as the target gene using a single round polymerase chain reaction (PCR) assay [16] . P. jirovecii detected from relevant respiratory clinical samples were further studied to detect DHPS gene by amplifi cation of DHPS gene using nested PCR protocol using Dp15/Dp800 as the primary primers and DHPS-NF/DHPS-NR as the secondary primers [17, 18] . The nested PCR conditions consisted of initial denaturation at 95 ° C for 3 min followed by 35 cycles at 94 ° C for 30 sec, 62 ° C for 30 sec and 72 ° C for 45 sec with a fi nal extension at 72 ° C for 5 min. All the PCR reactions were performed in an ABI 2720, thermocycler (Applied Biosystems, USA). Necessary precautions were taken during the performance of each PCR reaction to prevent carry-over contamination. Both pre-and post-PCR reactions were performed in different rooms and all the reagents were handled using barrier fi lter pipette tips. Multiple negative controls were run during each PCR assay. Amplifi ed products of MSG PCR and nested-DHPS PCR assays were run on 1.5% agarose gels containing ethidium bromide and the bands were visualized by UV light. MSG PCR and nested-DHPS PCR amplifi ed products of 250 bp and 186 bp, respectively ( Fig. 1 ) The 186 bp amplifi ed product was further purifi ed using QIAquick gel extraction kit (Qiagen, USA) according to the manufacturer ' s instructions. Purifi ed nested-DHPS PCR fragments were sequenced in an automated DNA sequencer (model 3130xl Genetic Analyzer, Applied Biosystems) using v.3.1 BigDye ® Terminator cycle sequencing kit (Applied Biosystems, USA). The primers used for sequencing were DHPS-NF and DHPS-NR [18] .
Results
Diagnosis of PCP was made in 24 (11.8%) cases of the total 203 non-HIV immunocompromised patients. Of the 24 patients, 15 were males and 9 were females with a median age of 26.5 years [range, 0.29 -62 years] . Different clinical respiratory specimens obtained from these 24 PCP positive cases included 21 bronchoalveolar lavage fl uid (BALF) and one sample each of sputum, nasopharyngeal aspirate and tracheal aspirates from three patients ( Table 1) . Fourteen (58.3%) of the 24 patients were determined to be positive by DFA staining, 7 (29.1%) were positive by Grocott ' s methenamine silver staining and all 24 were found positive by single round MSG PCR assay ( Table 2 ). The DHPS gene was amplifi ed by nested PCR protocol in all 24 clinical specimens that were positive for P. jirovecii by MSG PCR assay. Sequencing analysis showed 95.8% (23/24) of the P. jirovecii as being DHPS genotype 1 with the nucleotide sequence ACA CGG CCT at codons 55, 56 and 57, corresponding to threonine and proline amino acids at codon 55 and 57 (Thr55 ϩ Pro57), respectively. Whereas could not be performed and in one patient (4.1%) the treatment was changed to clindamycin plus primaquine combination for PCP.
Discussion
The distribution of P. jirovecii DHPS genotypes and its association to clinical outcome of PCP have been studied mainly in patients with HIV/AIDS primarily because P. jirovecii DHPS mutants are believed to occur in this population due to selective pressure of sulfa drugs [17] [20] in a study of the distribution of DHPS genotypes in 64 HIV negative subjects with different chronic pulmonary diseases and in 15 HIV patients. It was observed that DHPS genotype 1 was the most prevalent type (70%) in non-HIV patients compared to 54.5% in patients with AIDS and PCP ( P ϭ 0.63). However, the only patient (1/79) with DHPS genotype 4 (mutation at codon 55/57) had AIDS-associated PCP. A study conducted in China has shown a rate of only 7% (1/15) of DHPS mutation even in AIDS patients [21] and low rates of DHPS mutation have also been reported from developing countries like Thailand [13] and Brazil [22] . Thus, it appears that both rates of DHPS mutation, as well as the frequency of DHPS genotype 4 are much less in developing countries.
P. jirovecii DHPS genotype 4 was detected in 1 postrenal transplant (PRT) recipient who had not responded to standard cotrimoxazole treatment and was treated with clindamycin plus primaquine. The single case involving DHPS genotype 4 that was associated with sulfa treatment failure in the present study is of importance in that the patient had not received any sulfa prophylaxis and this was the fi rst episode of PCP during the present hospital admission. Takahashi et al . [23] described DHPS mutants in two patients with lymphoma (non-HIV immunocompromised individuals) who had no exposure to sulfa drugs. This demonstrates that DHPS mutations are not necessarily selected by the pressure of drug therapy and may be incidentally acquired. Such acquisition of mutant strain in predisposed the remaining one (4.1%) was DHPS genotype 4 with the nucleotide sequence GCA CGG TCT at codons 55, 56 and 57, corresponding to the amino acids alanine and serine at codon 55 and 57 (Thr55Ala ϩ Pro57Ser) based on the classifi cation described by Beard et al . [12] . A mutant P. jirovecii DHPS genotype was defi ned as any DNA sequence that differed from the wild type sequence.
Upon analysis of clinical features, dyspnoea was the predominant presenting illness in all cases followed by fever in 21 (87.5%, 21/24) and cough in 19 (79.1%, 19/24). Abnormal chest X-ray results were observed in almost all patients. Median arterial oxygen pressure (PaO 2 ) (Inter Quartile Range, IQR) was 53 (46.2 -60) mm Hg. Six (25%) of the patients were admitted to the intensive care unit (ICU) and required mechanical ventilation . All the 24 patients were hospitalized and none of them had any previous history of P. jirovecii pneumonia and/or had received anti-pneumocystis prophylaxis or treatment before hospital admission. Median duration of the hospital stay [IQR] was 21 days (14 -33) and while in the hospital all of them were treated with cotrimoxazole (TMP-SMX). Cotrimoxazole treatment was successful in 15 patients (62.5%, 15/24). Fatal outcome was documented in 8 patients (33.3%) during the course of TMP-SMX treatment for whom autopsies (9) Bronchoalveolar lavage fl uid (9) Pulmonary alveolar proteinosis (2) Bronchoalveolar lavage fl uid (2) Systemic lupus erythematosus (2) Bronchoalveolar lavage fl uid (2) Non-Hodgkin's lymphoma (2) Bronchoalveolar lavage fl uid (2) Metabolic liver disease (1) Bronchoalveolar lavage fl uid (1) Cushing's syndrome (1) Bronchoalveolar lavage fl uid (1) Crohn's disease (1) Tracheal aspirate (1) Myasthenia gravis (1) Sputum ( (1) Bronchoalveolar lavage fl uid (1) Autoimmune hepatitis (1) Nasopharyngeal aspirate (1) On steroids (1) Bronchoalveolar lavage fl uid (1) patients may pose as a potential reservoir for person-toperson transmission [24] . It is known that the prodrome duration of P. jirovecii infection is longer and the symptoms are milder in HIV positive patients despite a heavy microbial load. In contrast, immunocompromised HIV negative patients with P. jirovecii pneumonia may progress rapidly to respiratory failure. [25] . The patient with DHPS 4 genotype had a poor outcome that reinforces the fact that patients with mutant genotypes increasingly require mechanical ventilation and intensive care during clinical management of PCP [26] . In addition, this result indicates that DHPS genotype 4 may be a marker for poor clinical outcome. There are limited studies related to P. jirovecii DHPS genotypes in non-HIV immunocompromised patients from developing countries, which nonetheless is a very important high risk group for acquiring P. jirovecii infection as most of them are on intensive chemotherapy or on immunosuppressive therapy with steroids. Various workers have indicated that the DHPS mutations and their importance in P. jirovecii resistance are unresolved questions. It is also of signifi cance to note that the treatment cost, hospital cost and the difference between hospital cost and reimbursement (net cost) were found to be signifi cantly greater in HIV negative than in HIV positive patients [27] . Since this study had the limitation of small sample size, studies with large sample size are of utmost importance and warrants further survey on P. jirovecii DHPS genotypes circulating among non-HIV immunocompromised patients.
